Monte Rosa Therapeutics, Inc.
Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.
GLUE | NDAQ
Overview
Corporate Details
- ISIN(s):
- US61225M1027
- LEI:
- Country:
- United States of America
- Address:
- 321 HARRISON AVENUE, 2118 BOSTON
- Website:
- https://www.monterosatx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops highly selective molecular glue degrader (MGD) medicines. The company utilizes its proprietary drug discovery platform, which integrates expertise in MGD chemistry, artificial intelligence (AI), structural biology, and proteomics, to create therapies that degrade disease-causing proteins. This approach enables the targeting of proteins previously considered undruggable or inadequately drugged with high specificity. Monte Rosa's development programs are focused on pioneering new treatments for patients with serious diseases, including cancer and immune-mediated conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Monte Rosa Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Monte Rosa Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Monte Rosa Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
